Haemonetics Co. (NYSE:HAE) Shares Sold by Retirement Systems of Alabama

Retirement Systems of Alabama lowered its holdings in Haemonetics Co. (NYSE:HAE) by 0.3% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 177,569 shares of the medical instruments supplier’s stock after selling 513 shares during the period. Retirement Systems of Alabama owned approximately 0.35% of Haemonetics worth $14,273,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Commonwealth Equity Services LLC grew its stake in shares of Haemonetics by 3.3% in the second quarter. Commonwealth Equity Services LLC now owns 3,673 shares of the medical instruments supplier’s stock worth $304,000 after acquiring an additional 117 shares in the last quarter. Vontobel Holding Ltd. boosted its stake in shares of Haemonetics by 3.8% in the 3rd quarter. Vontobel Holding Ltd. now owns 4,878 shares of the medical instruments supplier’s stock valued at $392,000 after buying an additional 180 shares during the period. Arizona State Retirement System grew its position in shares of Haemonetics by 2.0% during the second quarter. Arizona State Retirement System now owns 14,217 shares of the medical instruments supplier’s stock worth $1,176,000 after buying an additional 272 shares in the last quarter. Keene & Associates Inc. increased its stake in shares of Haemonetics by 3.0% during the third quarter. Keene & Associates Inc. now owns 10,174 shares of the medical instruments supplier’s stock worth $818,000 after buying an additional 298 shares during the period. Finally, Versor Investments LP raised its holdings in Haemonetics by 9.1% in the third quarter. Versor Investments LP now owns 3,600 shares of the medical instruments supplier’s stock valued at $289,000 after acquiring an additional 300 shares in the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Haemonetics Trading Down 1.3 %

Shares of Haemonetics stock opened at $81.19 on Monday. The company has a debt-to-equity ratio of 1.39, a quick ratio of 2.09 and a current ratio of 3.49. The company has a market capitalization of $4.08 billion, a P/E ratio of 33.69, a PEG ratio of 1.29 and a beta of 0.38. Haemonetics Co. has a 1 year low of $70.25 and a 1 year high of $97.97. The company’s fifty day moving average is $81.06 and its two-hundred day moving average is $81.49.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.09 by $0.03. The firm had revenue of $345.50 million for the quarter, compared to analyst estimates of $342.57 million. Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. The business’s revenue was up 8.6% on a year-over-year basis. During the same quarter last year, the company posted $0.99 earnings per share. Analysts forecast that Haemonetics Co. will post 4.59 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have commented on HAE. JPMorgan Chase & Co. assumed coverage on shares of Haemonetics in a research report on Friday, December 6th. They issued an “overweight” rating and a $116.00 price objective on the stock. Citigroup dropped their price objective on Haemonetics from $94.00 to $85.00 and set a “neutral” rating on the stock in a report on Thursday, August 22nd. BTIG Research initiated coverage on Haemonetics in a research note on Tuesday, September 10th. They set a “buy” rating and a $112.00 target price for the company. Raymond James upgraded shares of Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 price target on the stock in a research note on Friday, November 8th. Finally, Needham & Company LLC reissued a “buy” rating and set a $112.00 price objective on shares of Haemonetics in a report on Tuesday, December 3rd. Three research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $108.78.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.